You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZomepirac
Accession NumberDB04828
TypeSmall Molecule
GroupsWithdrawn
DescriptionZomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.
Structure
Thumb
Synonyms
5-(4-Chlorobenzoyl)-1,4-dimethyl-1H-pyrrole-2-acetic acid
Zomepiracum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Zomepirac sodium
Thumb
  • InChI Key: SEEXPXUCHVGZGU-UHFFFAOYSA-M
  • Monoisotopic Mass: 313.048165669
  • Average Mass: 313.711
DBSALT000335
Categories
UNII822G987U9J
CAS number33369-31-2
WeightAverage: 291.73
Monoisotopic: 291.066221026
Chemical FormulaC15H14ClNO3
InChI KeyInChIKey=ZXVNMYWKKDOREA-UHFFFAOYSA-N
InChI
InChI=1S/C15H14ClNO3/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10/h3-7H,8H2,1-2H3,(H,18,19)
IUPAC Name
2-[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]acetic acid
SMILES
CN1C(CC(O)=O)=CC(C)=C1C(=O)C1=CC=C(Cl)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetophenones. These are organic compounds containing the acetophenone structure.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAcetophenones
Direct ParentAcetophenones
Alternative Parents
Substituents
  • Acetophenone
  • Aryl ketone
  • Benzoyl
  • Halobenzene
  • Chlorobenzene
  • Substituted pyrrole
  • N-methylpyrrole
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Pyrrole
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationZomepirac was indicated for the management of mild to severe pain.
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9714
Blood Brain Barrier+0.8608
Caco-2 permeable+0.7695
P-glycoprotein substrateNon-substrate0.7316
P-glycoprotein inhibitor INon-inhibitor0.9347
P-glycoprotein inhibitor IINon-inhibitor0.9287
Renal organic cation transporterNon-inhibitor0.7965
CYP450 2C9 substrateNon-substrate0.7288
CYP450 2D6 substrateNon-substrate0.8163
CYP450 3A4 substrateNon-substrate0.5337
CYP450 1A2 substrateNon-inhibitor0.7776
CYP450 2C9 inhibitorNon-inhibitor0.8844
CYP450 2D6 inhibitorNon-inhibitor0.8955
CYP450 2C19 inhibitorNon-inhibitor0.7741
CYP450 3A4 inhibitorNon-inhibitor0.8973
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8525
Ames testNon AMES toxic0.8817
CarcinogenicityNon-carcinogens0.8425
BiodegradationNot ready biodegradable0.9476
Rat acute toxicity2.7638 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9389
hERG inhibition (predictor II)Non-inhibitor0.8816
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point178.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.026 mg/mLALOGPS
logP3.37ALOGPS
logP3.33ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.86ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.3 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity77.2 m3·mol-1ChemAxon
Polarizability29.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

James B. Doherty, Debra L. Allison, “Process for the preparation of zomepirac and related compounds.” U.S. Patent US4374997, issued January, 1978.

US4374997
General ReferencesNot Available
External Links
ATC CodesM01AB04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabZomepirac may increase the anticoagulant activities of Abciximab.
AcebutololZomepirac may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Aceclofenac.
AcenocoumarolZomepirac may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Zomepirac.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Zomepirac.
Alendronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Alendronic acid.
AliskirenZomepirac may decrease the antihypertensive activities of Aliskiren.
AlprenololZomepirac may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Zomepirac.
AmikacinZomepirac may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideZomepirac may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Zomepirac can be decreased when combined with Amiodarone.
AncrodZomepirac may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Zomepirac.
Antithrombin III humanZomepirac may increase the anticoagulant activities of Antithrombin III human.
ApixabanZomepirac may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Zomepirac is combined with Apremilast.
AprepitantThe serum concentration of Zomepirac can be increased when it is combined with Aprepitant.
ArdeparinZomepirac may increase the anticoagulant activities of Ardeparin.
ArgatrobanZomepirac may increase the anticoagulant activities of Argatroban.
ArotinololZomepirac may decrease the antihypertensive activities of Arotinolol.
AtazanavirThe metabolism of Zomepirac can be decreased when combined with Atazanavir.
AtenololZomepirac may decrease the antihypertensive activities of Atenolol.
AtomoxetineThe metabolism of Zomepirac can be decreased when combined with Atomoxetine.
AzapropazoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Zomepirac.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zomepirac.
BalsalazideZomepirac may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Zomepirac.
BecaplerminZomepirac may increase the anticoagulant activities of Becaplermin.
BefunololZomepirac may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Zomepirac.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Zomepirac.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Zomepirac.
BetaxololZomepirac may decrease the antihypertensive activities of Betaxolol.
BevantololZomepirac may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Zomepirac can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Zomepirac.
BisoprololZomepirac may decrease the antihypertensive activities of Bisoprolol.
BivalirudinZomepirac may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Zomepirac can be decreased when combined with Boceprevir.
BopindololZomepirac may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Zomepirac can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Zomepirac can be decreased when it is combined with Bosentan.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zomepirac.
BufuralolZomepirac may decrease the antihypertensive activities of Bufuralol.
BumetanideZomepirac may decrease the diuretic activities of Bumetanide.
BupranololZomepirac may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Zomepirac.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Zomepirac.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Zomepirac.
CarbamazepineThe metabolism of Zomepirac can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Zomepirac.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Zomepirac.
CarteololZomepirac may decrease the antihypertensive activities of Carteolol.
CarvedilolZomepirac may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zomepirac.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Zomepirac.
CeliprololZomepirac may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Zomepirac can be increased when it is combined with Ceritinib.
CertoparinZomepirac may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Zomepirac.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zomepirac.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Zomepirac.
CholestyramineCholestyramine can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zomepirac.
Citric AcidZomepirac may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe metabolism of Zomepirac can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Zomepirac can be decreased when combined with Clemastine.
ClodronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Zomepirac.
ClotrimazoleThe metabolism of Zomepirac can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Zomepirac can be decreased when combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Zomepirac resulting in a reduced serum concentration and potentially a decrease in efficacy.
ConivaptanThe serum concentration of Zomepirac can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Zomepirac can be decreased when combined with Crizotinib.
CyclosporineZomepirac may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Zomepirac can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Zomepirac is combined with D-Limonene.
Dabigatran etexilateZomepirac may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Zomepirac can be decreased when it is combined with Dabrafenib.
DalteparinZomepirac may increase the anticoagulant activities of Dalteparin.
DanaparoidZomepirac may increase the anticoagulant activities of Danaparoid.
DarunavirThe metabolism of Zomepirac can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Zomepirac can be increased when it is combined with Dasatinib.
DaunorubicinZomepirac may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe serum concentration of Zomepirac can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Zomepirac is combined with Deferasirox.
DelavirdineThe metabolism of Zomepirac can be decreased when combined with Delavirdine.
DesirudinZomepirac may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin.
DexamethasoneThe serum concentration of Zomepirac can be decreased when it is combined with Dexamethasone.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Zomepirac.
DextranZomepirac may increase the anticoagulant activities of Dextran.
Dextran 40Zomepirac may increase the anticoagulant activities of Dextran 40.
Dextran 70Zomepirac may increase the anticoagulant activities of Dextran 70.
Dextran 75Zomepirac may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Zomepirac.
DicoumarolZomepirac may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zomepirac.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Zomepirac.
DihydroergotamineThe metabolism of Zomepirac can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinZomepirac may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe metabolism of Zomepirac can be decreased when combined with Diltiazem.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Zomepirac.
DoxorubicinZomepirac may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxycyclineThe metabolism of Zomepirac can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Zomepirac can be decreased when combined with Dronedarone.
DrospirenoneZomepirac may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Droxicam.
Edetic AcidZomepirac may increase the anticoagulant activities of Edetic Acid.
EdoxabanZomepirac may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Zomepirac can be decreased when it is combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Zomepirac.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Zomepirac.
EnoxaparinZomepirac may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Zomepirac can be decreased when it is combined with Enzalutamide.
EpirizoleThe risk or severity of adverse effects can be increased when Zomepirac is combined with Epirizole.
EpirubicinZomepirac may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneZomepirac may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zomepirac.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Zomepirac.
ErythromycinThe metabolism of Zomepirac can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Zomepirac can be decreased when it is combined with Eslicarbazepine acetate.
EsmololZomepirac may decrease the antihypertensive activities of Esmolol.
Etacrynic acidZomepirac may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Zomepirac.
Ethyl biscoumacetateZomepirac may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Zomepirac.
EtofenamateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Zomepirac.
EtravirineThe serum concentration of Zomepirac can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Zomepirac is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Zomepirac is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Zomepirac.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Zomepirac.
FluconazoleThe metabolism of Zomepirac can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Zomepirac.
FluvoxamineThe metabolism of Zomepirac can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Zomepirac.
Fondaparinux sodiumZomepirac may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Zomepirac.
FosamprenavirThe metabolism of Zomepirac can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Zomepirac can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Zomepirac.
FosphenytoinThe metabolism of Zomepirac can be increased when combined with Fosphenytoin.
FramycetinZomepirac may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideZomepirac may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Zomepirac can be increased when it is combined with Fusidic Acid.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Zomepirac.
GentamicinZomepirac may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Haloperidol.
HeparinZomepirac may increase the anticoagulant activities of Heparin.
HirulogZomepirac may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Zomepirac is combined with HMPL-004.
HydralazineZomepirac may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Zomepirac.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zomepirac.
Hygromycin BZomepirac may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Zomepirac.
IbuproxamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Zomepirac is combined with Icatibant.
IdarubicinZomepirac may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Zomepirac can be increased when it is combined with Idelalisib.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zomepirac.
ImatinibThe metabolism of Zomepirac can be decreased when combined with Imatinib.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Zomepirac.
IndenololZomepirac may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Zomepirac can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Zomepirac.
IndoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Zomepirac.
IsavuconazoniumThe metabolism of Zomepirac can be decreased when combined with Isavuconazonium.
IsoxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Isoxicam.
IsradipineThe metabolism of Zomepirac can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Zomepirac can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Zomepirac can be increased when it is combined with Ivacaftor.
KanamycinZomepirac may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Kebuzone.
KetoconazoleThe metabolism of Zomepirac can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Zomepirac.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Zomepirac.
LabetalolZomepirac may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Zomepirac.
LepirudinZomepirac may increase the anticoagulant activities of Lepirudin.
LevobunololZomepirac may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Zomepirac.
LithiumThe serum concentration of Lithium can be increased when it is combined with Zomepirac.
LopinavirThe metabolism of Zomepirac can be decreased when combined with Lopinavir.
LornoxicamThe risk or severity of adverse effects can be increased when Zomepirac is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Zomepirac.
LovastatinThe metabolism of Zomepirac can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Zomepirac.
LuliconazoleThe serum concentration of Zomepirac can be increased when it is combined with Luliconazole.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Zomepirac.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zomepirac.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Zomepirac.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zomepirac.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Zomepirac.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Zomepirac.
MesalazineZomepirac may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Zomepirac.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Zomepirac.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Zomepirac.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zomepirac.
MetipranololZomepirac may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zomepirac.
MetoprololZomepirac may decrease the antihypertensive activities of Metoprolol.
MetrizamideZomepirac may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe metabolism of Zomepirac can be decreased when combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Zomepirac.
MitotaneThe serum concentration of Zomepirac can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Zomepirac can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Zomepirac.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Zomepirac.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zomepirac.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zomepirac.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Zomepirac.
NadololZomepirac may decrease the antihypertensive activities of Nadolol.
NadroparinZomepirac may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Zomepirac can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Zomepirac.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Zomepirac.
NCX 4016The risk or severity of adverse effects can be increased when Zomepirac is combined with NCX 4016.
NefazodoneThe metabolism of Zomepirac can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Zomepirac can be decreased when combined with Nelfinavir.
NeomycinZomepirac may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Zomepirac is combined with Nepafenac.
NetilmicinZomepirac may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Zomepirac can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Zomepirac can be decreased when combined with Nevirapine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Zomepirac.
NilotinibThe metabolism of Zomepirac can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zomepirac.
OlaparibThe metabolism of Zomepirac can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Zomepirac.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zomepirac.
OlsalazineZomepirac may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Zomepirac.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Zomepirac.
OrgoteinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Orgotein.
OsimertinibThe serum concentration of Zomepirac can be increased when it is combined with Osimertinib.
OtamixabanZomepirac may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zomepirac.
OxprenololZomepirac may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Zomepirac.
PalbociclibThe serum concentration of Zomepirac can be increased when it is combined with Palbociclib.
PamidronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Zomepirac is combined with Parecoxib.
ParomomycinZomepirac may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololZomepirac may decrease the antihypertensive activities of Penbutolol.
PentobarbitalThe metabolism of Zomepirac can be increased when combined with Pentobarbital.
Pentosan PolysulfateZomepirac may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Zomepirac.
PhenindioneZomepirac may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Zomepirac can be increased when combined with Phenobarbital.
PhenprocoumonZomepirac may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Zomepirac.
PhenytoinThe metabolism of Zomepirac can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zomepirac.
PindololZomepirac may decrease the antihypertensive activities of Pindolol.
PiretanideZomepirac may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zomepirac.
PlicamycinZomepirac may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Zomepirac.
PosaconazoleThe metabolism of Zomepirac can be decreased when combined with Posaconazole.
PractololZomepirac may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Zomepirac.
PrimidoneThe metabolism of Zomepirac can be increased when combined with Primidone.
ProbenecidThe serum concentration of Zomepirac can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Zomepirac is combined with Propacetamol.
PropranololZomepirac may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Zomepirac.
Protein CZomepirac may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeZomepirac may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Zomepirac is combined with PTC299.
PuromycinZomepirac may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Zomepirac.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Zomepirac.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Zomepirac.
RanolazineThe metabolism of Zomepirac can be decreased when combined with Ranolazine.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Zomepirac.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Zomepirac.
ReviparinZomepirac may increase the anticoagulant activities of Reviparin.
RibostamycinZomepirac may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe metabolism of Zomepirac can be increased when combined with Rifabutin.
RifampicinThe metabolism of Zomepirac can be increased when combined with Rifampicin.
RifapentineThe metabolism of Zomepirac can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Risedronate.
RitonavirThe metabolism of Zomepirac can be decreased when combined with Ritonavir.
RivaroxabanZomepirac may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Zomepirac.
SalicylamideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Zomepirac.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Zomepirac.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Zomepirac.
SaquinavirThe metabolism of Zomepirac can be decreased when combined with Saquinavir.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Zomepirac.
SeratrodastThe risk or severity of adverse effects can be increased when Zomepirac is combined with Seratrodast.
SildenafilThe metabolism of Zomepirac can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Zomepirac can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Zomepirac can be increased when it is combined with Simeprevir.
SotalolZomepirac may decrease the antihypertensive activities of Sotalol.
SpectinomycinZomepirac may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Zomepirac.
SpironolactoneZomepirac may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Zomepirac is combined with SRT501.
St. John's WortThe serum concentration of Zomepirac can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Zomepirac can be increased when it is combined with Stiripentol.
StreptomycinZomepirac may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinZomepirac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineZomepirac may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zomepirac.
SulfisoxazoleThe metabolism of Zomepirac can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Zomepirac.
SulodexideZomepirac may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Zomepirac.
TacrolimusZomepirac may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Zomepirac.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Zomepirac.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Technetium Tc-99m Medronate.
TelaprevirThe metabolism of Zomepirac can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Zomepirac can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Zomepirac.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Zomepirac.
TenofovirThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Zomepirac.
TepoxalinThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Zomepirac is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zomepirac.
TiclopidineThe metabolism of Zomepirac can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tiludronate.
TimololZomepirac may decrease the antihypertensive activities of Timolol.
TobramycinZomepirac may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe serum concentration of Zomepirac can be decreased when it is combined with Tocilizumab.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Zomepirac.
TorasemideZomepirac may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Zomepirac.
TranilastThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Zomepirac.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Zomepirac.
TriamtereneZomepirac may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Zomepirac.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Zomepirac.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Zomepirac.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Zomepirac.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Zomepirac.
VenlafaxineThe metabolism of Zomepirac can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Zomepirac can be decreased when combined with Verapamil.
VoriconazoleThe metabolism of Zomepirac can be decreased when combined with Voriconazole.
WarfarinZomepirac may increase the anticoagulant activities of Warfarin.
XimelagatranZomepirac may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zomepirac is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Zomepirac.
ZiprasidoneThe metabolism of Zomepirac can be decreased when combined with Ziprasidone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Zomepirac is combined with Zoledronic acid.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Prostaglandin j receptor activity
Specific Function:
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is also implicated in mediating PTGDR2 effects. PGD2 induced receptor internalization. CRTH2 internalization can be regulated by diverse kinases such as, PKC, PKA, ADRBK1/GRK2, GPRK5/GRK5 and GRK6. Recepto...
Gene Name:
PTGDR2
Uniprot ID:
Q9Y5Y4
Molecular Weight:
43267.15 Da
References
  1. Hata AN, Lybrand TP, Marnett LJ, Breyer RM: Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Mol Pharmacol. 2005 Mar;67(3):640-7. Epub 2004 Nov 24. [PubMed:15563582 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 14:33 / Updated on August 17, 2016 12:24